Radioimmunotherapy of nude mice with intraperitoneally growing ovarian cancer xenograft utilizing 211At-labelled monoclonal antibody MOv18

Anticancer Research

Volumn 20, Issue 1 A, 2000, Pages 459-462

  Andersson, Hakan ^a   Lindegren, Sture ^a   Back, Tom ^a   Jacobsson, Lars ^a   Leser, Gunilla ^a   Horvath, György ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

211Astatine; Ovarian cancer; Radioimmunotherapy

Indexed keywords

ASTATINE 211; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MOV18; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCITES; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; OVARY CANCER; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; ASCITES; ASTATINE; CARCINOMA; CARRIER PROTEINS; FEMALE; HUMANS; IMMUNOCONJUGATES; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; NEOPLASM, RESIDUAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; RADIOIMMUNOTHERAPY; RECEPTORS, CELL SURFACE; TRANSPLANTATION, HETEROLOGOUS;

EID: 0034073153     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL and Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1-6, 1996.
2. Markman M: Intraperitoneal therapy of ovarian cancer. Semin Oncol 25: 356-360, 1998.
3. Hird V, Maraveyas A, Snook D, Dhokia B, Soutter WP, Meares C, Stewart JSW, Mason P. Lambert HE and Epenetos A: Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br J Cancer 68: 403-406, 1993.
4. Crippa F, Bolis G, Seregni E, Gavoni N, Scarfone G, Ferraris C, Buraggi GL and Bombardieri E: Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody 1-131 MOv18: clinical results in patients with minimal residual disease of ovarian cancer. Eur J Cancer 31A: 686-690, 1995.
5. Zalutsky MR, McLendon RE, Garg PK, Archer GE, Schuster JM and Bigner DD: Radioimmunotherapy of neoplatic meningitis in rats using an alpha-particle-emitting immunoconjugate. Cancer Res 54: 4719-4725, 1994.
6. 125I according to the m-Me-ATE method or the Iodogen method in nude mice with ovarian cancer xenografts. Acta Oncol 38: 323-328, 1999.
7. Lindegren S, Skarnemark G, Jacobsson L and Karlsson B: Chloramine-T in high-specific-activity radioiodination of antibodies using N-succinimidyl-3-(trimethylstannyl)benzoate as an intermediate. Nucl Med Biol 25: 659-665, 1998.
8. Boerman OC, van Niekerk CC, Makkink K, Hanselaar TGJM, Kenemans P and Poels LG: Comparative immunohistochemical study of four monoclonal antibodies directed against ovarian carcinoma-associated antigens. Int J Gyn Path 10: 15-25, 1991.
9. Miotti S, Canevari S, Me'nard S, Mezzanzanica D, Porro G, Pupa SM, Regazzoni M, Tagliabue E and Colnaghi MI: Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int J Cancer 39: 297-303, 1987.
10. Campbell IG, Jones TA, Foulkes WD and Trowsdale J: Folate-binding protein is a marker for ovarian cancer. Cancer Res 51: 5329-5338, 1991.
11. Hamilton TC, Young RC, Louie KG, Behrens BC, McKoy WM, Grotzinger KR and Ozols RF: Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice. Cancer Res 44: 5286-5290, 1984.
12. Horak E, Hartmann F, Garmestani K, Wu C, Brechbiel M, Gansow OA, Landolfi NF and Waldman TA: Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1. J Nucl Med 38: 1944-1950, 1997.
13. Manetta A, Sataswaroop PG, Hamilton T, Ozolos R and Mortel R: Therapeutic effect of radiolabeled antibody on human ovarian cancer xenografts in nude mice. Gynecol Oncol 32: 368-370, 1989.
14. Tibben JG, Massuger LFAG, Boerman OC, Borm GF, Classens RAMJ and Corstens FHM: Effect of the route of administration on the biodistribution of radioiodinated OV-TL 3F(ab')2 in experimental ovarian cancer. Eur J Nucl Med 21: 1183-1190, 1994.
15. Senekowitsch R, Schmid P, Mollenstadt S, Kriegel H and Pabst HW: Experimental model for radioimmunotherapy of human ovarian carcinoma with I-131-labeled monoclonal antibody OC 125. Strahlenther Onkol 165: 564-566, 1989.
16. Macklis RM, Kaplan WD, Ferrara JLM, Atcher RW, Hines JJ, Burakoff SJ and Colemna CN: Resident's essay award:alpha particle radioimmunotherapy: animal models and clinical prospects. Int J Radiat Oncol Biol Phys 16: 1377-1387, 1988.
17. 211At in a murine intraperitoneal tumor model. Gynecol Oncol 57: 9-15, 1995.
18. Maraveyas A and Epenetos A: Targeted immunotherapy. An update with special emphasis on ovarian cancer. Acta Oncol 32: 741-746, 1993.
19. Muto MG, Finkler NJ, Kassis Al, Howes AE, Anderson LL, Lau CC, Zurawski Jr VR, Weadock K, Tumeh SS, Lavin P and Knapp RC: Intraperitoneal radioimmunotherapy of refractory ovarian carcinoma utilizing iodine-131-labeled monoclonal antibody OC 125. Gynecol Oncol 45: 265-272, 1992.
20. 211At]astatide in B6C3F1 and BALB/c (nu/nu) mice: a long-term survival study with histologic analysis. Int J Radiat Oncol Biol Phys 35: 69-80, 1996.
21. Cobb LM, Harrison A and Butler SA: Toxicity of Astatine-211 in the mouse. Hum Toxicol 7: 529-534, 1988.
22. Cobb LM, Butler SA and Harrison A: The effect of the alpha-particle-emitter Astatine-211 in the mouse at the minimum toxic dose. Hum Exp Toxicol 9: 289-293, 1990.
23. Wahl RL, Barrett J, Geatti O, Liebert M, Wilson BS, Fisher S and Wagner JG: The intraperitoneal delivery of radiolabeled monoclonal antibodies:studies on the regional delivery advantage. Cancer Immunol Immunother 26: 187-201, 1988.
24. Rowlinson G, Snook D, Busza A and Epenetos AA: Antibody-guided localization of intraperitoneal tumors following intraperitoneal or intravenous antibody administration. Cancer Res 47: 6528-6531, 1987.
25. Crippa F, Buraggi GL, Di-Re E, Gasparini M, Seregni E., Canevari S, Gadina M, Presti M, Marini A and Seccamani E: Radioimmunoscintigraphy of ovarian cancer with the MOv 18 monoclonal antibody. Eur J Cancer 27: 724-729, 1991.
26. Ward BG and Wallace K: Localization of the monoclonal antibody HMFG2 after intravenous and intraperitoneal injection into nude mice bearing subcutaeous and intraperitoneal human ovarian cancer xenografts. Cancer Res 47: 4714-4718, 1987.